Intensity Therapeutics, Inc.
INTS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001567264
No open-market purchases or sales by Intensity Therapeutics, Inc. insiders were filed in the last 90 days; 17 institutions reported holding it in 13F filings for Q2 2026, worth $4.79M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Intensity Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 18 | 23 | +5 |
| Shares | 1.63M | 1.68M | +46.2K (+2.8%) |
| Value | $8.49M | $8.23M | −$260.0K (−3.1%) |
New holders (5)
Institutions that held Intensity Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Blair William & Co | 37,805 | $185.2K | 0.00% |
| HRT Financial LP | 15,863 | $77.0K | 0.00% |
| Steward Partners Investment Advisory, LLC | 900 | $4.41K | 0.00% |
| Morgan Stanley | 500 | $2.45K | 0.00% |
| Bank of America Corp | 219 | $1.07K | 0.00% |
Sold out (0)
Institutions that held Intensity Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
None.